TNGX Q1 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+12.2% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$42M-653.0% margin

Net Income

-$38M-585.9% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+19.1%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$406M

Total Liabilities

$142M

Stockholders' Equity

$264M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	+12.2%
Gross Profit	$6M	$4M	+50.2%
Operating Income	-$42M	-$30M	-39.5%
Net Income	-$38M	-$28M	-35.4%